In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Drug maker Moderna 's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook ...

hospitalization,” Moderna CEO Stéphane Bancel said in a Sept. 30 news release. “By advancing our investigational norovirus vaccine into a pivotal Phase 3 trial, we are one step closer to ...

CEO Stéphane Bancel said the vaccine maker aims to reduce ... on the application for its next-generation COVID-19 vaccine, Moderna said. Moderna expects to report data from a trial of its ...